These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23148192)

  • 21. Coronavirus Disease 2019 (SARS-CoV-2) and polycystic ovarian disease: Is there a higher risk for these women?
    Morgante G; Troìa L; De Leo V
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105770. PubMed ID: 33065278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
    Sam S; Scoccia B; Yalamanchi S; Mazzone T
    Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin and the polycystic ovary syndrome.
    Macut D; Bjekić-Macut J; Rahelić D; Doknić M
    Diabetes Res Clin Pract; 2017 Aug; 130():163-170. PubMed ID: 28646699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China.
    Wang L; Lv S; Li F; Yu X; Bai E; Yang X
    Front Endocrinol (Lausanne); 2020; 11():171. PubMed ID: 32296394
    [No Abstract]   [Full Text] [Related]  

  • 27. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension in Polycystic Ovary Syndrome: Novel Insights.
    Macut D; Mladenović V; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Andrić Z
    Curr Hypertens Rev; 2020; 16(1):55-60. PubMed ID: 31146668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications and challenges associated with polycystic ovary syndrome: current perspectives.
    Palomba S; Santagni S; Falbo A; La Sala GB
    Int J Womens Health; 2015; 7():745-63. PubMed ID: 26261426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of obesity and polycystic ovary syndrome in adolescents.
    Vilmann LS; Thisted E; Baker JL; Holm JC
    Horm Res Paediatr; 2012; 78(5-6):269-78. PubMed ID: 23208318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance and β-cell dysfunction and the relationship with cardio-metabolic disorders among women with polycystic ovary syndrome.
    Mu L; Zhao Y; Lai Y; Li R; Qiao J
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):779-788. PubMed ID: 30106166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.
    Economou F; Xyrafis X; Christakou C; Diamanti-Kandarakis E
    Curr Pharm Des; 2011; 17(9):908-21. PubMed ID: 21418035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome.
    Wang J; Wu D; Guo H; Li M
    Life Sci; 2019 Nov; 236():116940. PubMed ID: 31604107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic consequences of polycystic ovary syndrome.
    Churchill SJ; Wang ET; Pisarska MD
    Minerva Ginecol; 2015 Dec; 67(6):545-55. PubMed ID: 26372304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic ovary syndrome in adolescents.
    Franks S
    Int J Obes (Lond); 2008 Jul; 32(7):1035-41. PubMed ID: 18458678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovary syndrome and the metabolic syndrome.
    Weerakiet S
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S189-93. PubMed ID: 21213522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome.
    Liang SJ; Liou TH; Lin HW; Hsu CS; Tzeng CR; Hsu MI
    Acta Obstet Gynecol Scand; 2012 Oct; 91(10):1167-72. PubMed ID: 22497305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies.
    Barber TM; Hanson P; Weickert MO; Franks S
    Clin Med Insights Reprod Health; 2019; 13():1179558119874042. PubMed ID: 31523137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
    Sirmans SM; Weidman-Evans E; Everton V; Thompson D
    Ann Pharmacother; 2012 Mar; 46(3):403-18. PubMed ID: 22388330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome in polycystic ovary syndrome.
    Essah PA; Nestler JE
    J Endocrinol Invest; 2006 Mar; 29(3):270-80. PubMed ID: 16682845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.